The use of etanercept and infliximab, which are anti-TNF-α agents, has led to improvement in endothelial function along with RA symptoms compared to other disease-modifying agents such as penicillamine and sulfasalazine [15]. This evidence concerns the gene TNF and rheumatoid arthritis.